After Dianthus (DNTH) Therapeutics announced top-line data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart in adults with acetylcholine receptor antibody positive generalized Myasthenia Gravis, Jefferies analyst Maury Raycroft contends that the data derisks claseprubart with a path forward to a potential registrational study in gMG and derisks efficacy and dosing for programs in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. The firm has a Buy rating and $51 price target on Dianthus shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus price target raised to $72 at Evercore after ‘bull case outcome’
- Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX
- Dianthus Therapeutics Reports Positive Phase 2 Trial Results
- Promising Phase 2 Results and Market Potential Drive Buy Rating for Dianthus Therapeutics’ Claseprubart
- Dianthus Therapeutics: Promising Phase II Results and Expanding Market Potential Justify Buy Rating